Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Findings likely to generate hypotheses about potential new uses of drugs
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Subscribe To Our Newsletter & Stay Updated
